Abstract
In the last few years, the fields of Medicinal Chemistry and especially the ones related to the so-called Personalized Medicine, have received a great attention. Significant investment and remarkable researches surround the matter; however, not all those promising advances are reaching patients as quickly as they should. The absence of an adequate regulatory framework could be of no help. The complete and/or massive sequencing of individual genomes faces many ethical-legal challenges. Some of them are access to Personalized Medicine; the treatment of a large volume of sensitive information and the use of tools produced by "big data" systems in clinical care or in predictive models. In addition, the legal protection of personal data related to health, the exercise of autonomy by patients, closely related to the regulation regarding clinical trials, are seriously involved. Our purpose of this work is to review the regulations of the European Union, in an attempt to contribute to a better understanding of the legal framework for the implementation and development of health systems based on Personalized Medicine.
Keywords: Personalized medicine, Medicinal chemistry, Legal issues, Genomics, Data protection, Clinical trials.
Current Topics in Medicinal Chemistry
Title:Personalized Medicine and Medicinal Chemistry: Toward a Legal Framework in the European Union
Volume: 18 Issue: 25
Author(s): Aliuska Duardo-Sánchez*Iñigo De Miguel Beriain
Affiliation:
- Department of Public Law, Chair in Law and Human Genome Research Group, University of the Basque Country UPV/EHU, 48940, Leioa, Biscay,Spain
Keywords: Personalized medicine, Medicinal chemistry, Legal issues, Genomics, Data protection, Clinical trials.
Abstract: In the last few years, the fields of Medicinal Chemistry and especially the ones related to the so-called Personalized Medicine, have received a great attention. Significant investment and remarkable researches surround the matter; however, not all those promising advances are reaching patients as quickly as they should. The absence of an adequate regulatory framework could be of no help. The complete and/or massive sequencing of individual genomes faces many ethical-legal challenges. Some of them are access to Personalized Medicine; the treatment of a large volume of sensitive information and the use of tools produced by "big data" systems in clinical care or in predictive models. In addition, the legal protection of personal data related to health, the exercise of autonomy by patients, closely related to the regulation regarding clinical trials, are seriously involved. Our purpose of this work is to review the regulations of the European Union, in an attempt to contribute to a better understanding of the legal framework for the implementation and development of health systems based on Personalized Medicine.
Export Options
About this article
Cite this article as:
Duardo-Sánchez Aliuska *, De Miguel Beriain Iñigo , Personalized Medicine and Medicinal Chemistry: Toward a Legal Framework in the European Union, Current Topics in Medicinal Chemistry 2018; 18 (25) . https://dx.doi.org/10.2174/1568026619666181120144213
DOI https://dx.doi.org/10.2174/1568026619666181120144213 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Raloxifene
Current Drug Targets Photo- and Sono-Dynamic Therapy: A Review of Mechanisms and Considerations for Pharmacological Agents Used in Therapy Incorporating Light and Sound
Current Pharmaceutical Design The Sodium-Iodide Symporter
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Helicases as Prospective Targets for Anti-Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Beyond Hemostasis: The Role of Platelets in Inflammation, Malignancy and Infection
Cardiovascular & Hematological Disorders-Drug Targets Epithelial-Mesenchymal Transitions and Cancer
Current Genomics Advances in Development of Inhibitors of 17β-Hydroxysteroid Dehydrogenases
Anti-Cancer Agents in Medicinal Chemistry Tumor-Targeting Peptides: Ligands for Molecular Imaging and Therapy
Anti-Cancer Agents in Medicinal Chemistry Indole-3-Carbinol (I3C) and its Major Derivatives: Their Pharmacokinetics and Important Roles in Hepatic Protection
Current Drug Metabolism Capsaicin and Its Analogues: Structure-Activity Relationship Study
Current Medicinal Chemistry Effects of Salinomycin on Cancer Stem Cell in Human Lung Adenocarcinoma A549 Cells
Medicinal Chemistry PI3K Signaling in Chronic Obstructive Pulmonary Disease: Mechanisms, Targets, and Therapy
Current Medicinal Chemistry The Global Component-Target Network in Panax Ginseng C
Letters in Drug Design & Discovery Evaluation of Angiogenesis Process after Metformin and LY294002 Treatment in Mammary Tumor
Anti-Cancer Agents in Medicinal Chemistry Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin
Current Cancer Drug Targets Experimental Validation of an Assembly of Optimized Curved Rectangular Coils for the Use in Dynamic Field Free Line Magnetic Particle Imaging
Current Medical Imaging The Role of PET/CT and SPECT/CT in Oncology Drug Development
Current Molecular Imaging (Discontinued) Is there U-turn from Insulin Back to Pills in Diabetes?
Current Vascular Pharmacology Simple C-2-Substituted Quinolines and their Anticancer Activity
Letters in Drug Design & Discovery WNT Signaling in Stem Cell Biology and Regenerative Medicine
Current Drug Targets